Antioxidant activity of idebenone-loaded neutral and cationic solid-lipid nanoparticles

Pharmaceutical Development and Technology

Volumn 20, Issue 6, 2015, Pages 716-723

  Leonardi, Antonio ^a   Crascí, Lucia ^a   Panico, Annamaria ^a   Pignatello, Rosario ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Drug delivery; Idebenone; Nanomedicine; Solid lipid nanoparticles

Indexed keywords

DIDECYLDIMETHYLAMMONIUM BROMIDE; IDEBENONE; NANOCARRIER; PALMITIC ACID; POLYSORBATE 80; QUATERNARY AMMONIUM DERIVATIVE; SOLID LIPID NANOPARTICLE; STEARIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIOXIDANT; CATION; DRUG CARRIER; LIPID; NANOPARTICLE; REACTIVE OXYGEN METABOLITE; UBIQUINONE;

ANTIOXIDANT ACTIVITY; ARTICLE; COLLOID; CONTROLLED STUDY; DRUG DEGRADATION; NANOENCAPSULATION; ORAC ASSAY; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL;

ANTIOXIDANTS; CATIONS; DRUG CARRIERS; LIPIDS; NANOPARTICLES; REACTIVE OXYGEN SPECIES; UBIQUINONE;

EID: 84964194250     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2014.915572     Document Type: Article

References (37)

1. Suno M, Nagaoka A. Inhibition of lipid peroxidation by idebenone in brain mitochondria in the presence of succinate. Arch Gerontol Geriatr 1989; 8: 291-297.
2. Rauchova H, Vrbacky M, Bergamini C, et al. Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone. Biochem Biophys Res Commun 2006; 339: 362-366.
3. Carbone C, Cupri S, Leonardi A, et al. Lipid-based nanocarriers for drug delivery and targeting: A patent survey of methods of production and characterization. Pharma Pat Analyst 2013; 2: 665-677.
4. Sugiyama Y, Fujita T, Matsumoto M, et al. Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs. J Pharmacobiodyn 1985; 8: 1006-1017.
5. Haefeli RH, Erb M, Gemperli AC, et al. NQO1-dependent redox cycling of idebenone: Effects on cellular redoxpotential and energy levels. PLoS One 2011; 6: E17963.
6. Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: Current status and future prospects. Curr Med Chem 2011; 18: 3871-3888.
7. Giorgio V, Petronilli V, Ghelli A, et al. The effects of idebenone on mitochondrial bioenergetics. Biochim Biophys Acta 2012; 1817: 363-369.
8. Becker C, Bray-French K, Drewe J. Pharmacokinetic evaluation of idebenone. Expert Opin Drug Metab Toxicol 2010; 6: 1437-1434.
9. Orsucci D, Mancuso M, Ienco EC, et al. Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. Curr Med Chem 2011; 18: 4053-4064.
10. Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies. Prog Retin Eye Res 2011; 30: 81-114.
11. Barnils N, Mesa E, Muñoz S, et al. Response to idebenone and multivitamin therapy in Leber's hereditary optic neuropathy. Arch Soc Esp Oftalmol 2007; 82: 377-380.
12. Sabet-Peyman EJ, Khaderi KR, Sadun AA. Is leber hereditary optic neuropathy treatable? Encouraging results with idebenone in both prospective and retrospective trials and an illustrative case. J Neuro Ophthalmol 2012; 32: 54-57.
13. Sadun AA, La Morgia C, Carelli V. Leber's hereditary optic neuropathy, current treatment options in neurology. Curr Treat Options Neurol 2011; 13: 109-117.
14. Heitz FD, Erb M, Anklin C, et al. Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy. PLoS One 2012; 7: E45182.
15. Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011; 134: 2677-2686.
16. Carelli V, La Morgia C, Valentino ML, et al. Idebenone treatment in Leber's hereditary optic neuropathy. Brain 2011; 134: E188.
17. Iyer S. Novel therapeutic approaches for Leber's hereditary optic neuropathy. Discov Med 2013; 15: 141-149.
18. Muller RH, Mader K, Gohla S. Solid-lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177.
19. Muller RH, Shegokar R, Keck CM. 20 Years of lipid nanoparticles (SLN & NLC): Present state of development & industrial applications. Curr Drug Discov Technol 2011; 8: 207-227.
20. Stancampiano AH, Acquaviva R, Campisi A, et al. Technological and biological characterization of idebenone-loaded solid-lipid nanoparticles prepared by a modified solvent injection technique. J Biomed Nanotechnol 2006; 2: 253-260.
21. Montenegro L, Campisi A, Sarpietro MG, et al. In vitro evaluation of idebenone-loaded solid-lipid nanoparticles for drug delivery to the brain. Drug Dev Ind Pharm 2011; 37: 737-746.
22. Montenegro L, Trapani A, Latrofa A, Puglisi G. In vitro evaluation on a model of blood brain barrier of idebenoneloaded solid-lipid nanoparticles. J Nanosci Nanotechnol 2012; 12: 330-337.
23. Montenegro L, Sinico C, Castangia I, et al. Idebenone-loaded solid- lipid nanoparticles for drug delivery to the skin: In vitro evaluation. Int J Pharm 2012; 434: 169-174.
24. Merrell JG, McLaughlin SW, Tie L, et al. Curcumin-loaded poly(epsilon-caprolactone) nanofibres: Diabetic wound dressing with anti-oxidant and anti-inflammatory properties. Clin Exp Pharmacol Physiol 2009; 36: 1149-1156.
25. Li B, Ge Z-Q. Nanostructured lipid carriers improve skin permeation and chemical stability of idebenone. AAPS PharmSciTech 2012; 13: 276-283.
26. Fangueiro JF, Gonzalez-Mira E, Martins-Lopes P, et al. A novel lipid nanocarrier for insulin delivery: Production, characterization and toxicity testing. Pharm Dev Technol 2013; 18: 545-549.
27. Fangueiro JF, Andreani T, Egea MA, et al. Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity. Int J Pharm 2014; 461: 64-73.
28. Manosroi A, Thathang K, Werner RG, et al. Development of highly stable and lo toxic cationic liposomes for gene therapy. Arzneimittelforschung 2008; 58: 485-492.
29. Masotti A, Mossa G, Cametti C, et al. Comparison of different commercially available cationic liposome-DNA lipoplexes: Parameters influencing toxicity and transfection efficiency. Colloids Surf B Biointerfaces 2009; 68: 136-144.
30. Liebert MA. Final Report on the safety assessment of oleic acid, lauric acid, palmitic acid, myristic acid, and stearic acid. Int J Toxicol 1987; 6: 321-401.
31. HERA: Human & Environmental Risk Assessment on ingredients of European household cleaning products. Fatty Acid Salts - Human Health Risk Assessment, 2002. Available from: Http: //www. heraproject.com/files/5-HH-04-HERA%20Fatty%20acid%20salts% 20HH%20web%20wd.pdf [last accessed April 2014].
32. Martins De Lima T, Cury-Boaventura MF, et al. Comparative toxicity of fatty acids on a macrophage cell line (J774). Clin Sci 2006; 111: 307-317.
33. Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf B Biointerfaces 2010; 81: 412-421.
34. Kalam MA, Sultana Y, Ali A, et al. Preparation, characterization, and evaluation of gatifloxacin loaded solid-lipid nanoparticles as colloidal ocular drug delivery system. J Drug Target 2010; 18: 191-204.
35. González-Mira E, Nikolić S, García ML, et al. Potential use of nanostructured lipid carriers for topical delivery of flurbiprofen. J Pharm Sci 2011; 100: 242-251.
36. Basha M, Abd El-Alim SH, Shamma RN, Awad GE. Design and optimization of surfactant-based nanovesicles for ocular delivery of clotrimazole. J Liposome Res 2013; 23: 203-210.
37. Hippalgaonkar K, Adelli GR, Hippalgaonkar K, et al. Indomethacinloaded solid-lipid nanoparticles for ocular delivery: Development, characterization, and in vitro evaluation. J Ocul Pharmacol Ther 2013; 29: 216-228.